On June 29th, the award ceremony for the VB-Link Future Medical Specialty Innovative Solution Challenge (hereinafter referred to as the VB-Link Competition) was held at the Intercontinental Hotel in Jiabao, Tianjin Economic-Technological Development Area. After intense competition at the national finals, Hopstem's "iPSC Cell Therapy Products and Organoids Platform" project won the third prize in the field of neurology.
Based on the winning projects of this competition, they cover various areas such as innovative medical devices, biopharmaceuticals, and digital therapies, including organoids platforms, plant intervention devices, ophthalmic surgical robots, gene therapy drugs, etc. The types are diverse and novel, injecting fresh blood into the industry for high-quality development.
Hopstem Receives U.S. FDA IND Clearance and Fast Track designations for hNPC01 in Hemorrhagic Stroke and Traumatic Brain Injury-Expanding Clinical Development Across Three Major Brain Injury Indications
Hopstem hNPC01 Earns FDA RMAT Designation for Chronic Stroke Therapy
FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study
Hopstem Announces FDA Granted iPSC Therapy hNPC01 Injection Fast Track Designation, Accelerating Global Breakthrough in Treatment of Cerebral Neural Injury Diseases
R&D Center: Building 11,Heda Medicine Valley V, Qiantang Area,
Hangzhou, Zhejiang, China
Manufacturing Center: 3rd & 4th Floor, Building 10,Heda Medicine Valley lll,
Qiantang Area, Hangzhou, Zhejiang, China
U.S. Office: 103 Carnegie center, Suite 300, Princeton,
NJ 08540, USA
